Thursday, April 22, 2021

Bharat Biotech says Covid-19 vaccine shows 81% interim efficacy, Health News, ET HealthWorld

Follow Us on Social Media

Bharat Biotech says Covid-19 vaccine shows 81% interim efficacyBharat Biotech‘s homegrown Covid-19 vaccine has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Indian company said on Wednesday.

The interim analysis was based on 43 recorded cases of Covid-19 in the trial of 25,800 participants, conducted in partnership with the Indian government’s medical research body.

Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine, pointing to an efficacy rate of 80.6%, the company said.

India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness.

India’s vaccination drive, currently underway, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca.

Earlier this week, Indian Prime Minister Narendra Modi was inoculated with the first dose of COVAXIN.



Source link

Latest news

All countries
18,467,561
Total Active Covid19 Cases
Updated on April 22, 2021 1:23 am

Related news